SAB Biotherapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by SAB Biotherapeutics, Inc. on July 17, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbols SABS (Common Stock) and SABSW (Warrants).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
At the Annual Meeting, 6,633,125 shares were present, representing approximately 71.38% of the 9,291,697 shares entitled to vote, constituting a quorum. Shareholders approved two proposals:
- Proposal 1: Election of Class I Directors
- Dr. William Polvino, MD: 4,327,617 votes For; 150,831 Withheld.
- Scott Giberson: 4,312,205 votes For; 166,243 Withheld.
- Erick Lucera: 4,344,710 votes For; 133,738 Withheld.
- Dr. Jay S. Skyler, MD: 4,331,262 votes For; 147,186 Withheld.
- All four directors were elected to serve for a term of three years.
- Proposal 2: Ratification of Independent Auditor
- EisnerAmper LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 6,374,363; Votes Against: 238,327; Abstentions: 20,435.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new three-year terms for the elected Class I directors.
- Verification of the appointment of EisnerAmper LLP as the auditor for the 2025 fiscal year.
- Review of the significant number of broker non-votes (2,154,677) recorded for the director elections.
- Assessment of the 71.38% shareholder participation rate at the Annual Meeting.